Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 23andMe Holding Co. ME

Consumer Cyclical Healthcare Advertising Agencies
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including... see more

Recent & Breaking News (NDAQ:ME)

23andMe Reports Third Quarter Fiscal 2024 Financial Results

GlobeNewswire February 7, 2024

DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected

Accesswire February 7, 2024

DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected

Accesswire February 6, 2024

INVESTIGATION ALERT: Levi & Korsinsky, LLP Reminds Consumers of an Investigation of the 23andMe Hold

Accesswire January 31, 2024

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

GlobeNewswire January 31, 2024

23andMe Launches Month-Long Initiative to Amplify ARRAY's "Seat16" Program for Acclaimed Film ORIGIN by Ava DuVernay

GlobeNewswire January 30, 2024

INVESTIGATION ALERT: Levi & Korsinsky, LLP Reminds Consumers of an Investigation of the 23andMe Hold

Accesswire January 30, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire January 29, 2024

23andMe Holding Co (NASDAQ: ME) Data Breach- Levi & Korsinsky, LLP Investigates on Behalf of Consume

Accesswire January 26, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire January 25, 2024

23andMe to Report FY2024 Third Quarter Financial Results

GlobeNewswire January 24, 2024

DATA BREACH- 23andMe Holding Co Consumers May be Affected

Accesswire January 24, 2024

23andMe Holding Co (NASDAQ: ME) Data Breach- Levi & Korsinsky, LLP Investigates on Behalf of Consume

Accesswire January 23, 2024

23andMe Holding Co (NASDAQ:ME) Data Breach - Levi & Korsinsky, LLP Investigates on Behalf of Consume

Accesswire January 22, 2024

DATA BREACH- 23andMe Holding Co Consumers May be Affected

Accesswire January 19, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire January 18, 2024

23andMe Holding Co (NASDAQ: ME) Data Breach- Levi & Korsinsky, LLP Investigates on Behalf of Consume

Accesswire January 17, 2024

23andMe Holding Co (NASDAQ:ME) Data Breach - Levi & Korsinsky, LLP Investigates on Behalf of Consume

Accesswire January 16, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire January 15, 2024

23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts

GlobeNewswire December 19, 2023